Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SYN1002

Financiado

Cerrado

A New Therapeutic Option to Protect Central Nervous System against Acute Ischemi...

A New Therapeutic Option to Protect Central Nervous System against Acute Ischemic Stroke Each year, about 16 million strokes occur in the world causing millions of deaths and one third of patients experiencing permanent disability. The main treatment of stroke is thrombolytic agent recombinant tissue plasminogen activ... ver más

31/01/2018

ORPHIT

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

ORPHIT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-01-31

SMEInst-03-2016-2017: Dedicated support to biotechnology...

I+D

Cerrada hace 8 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ORPHIT

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

COUNTERSTROKE Treating stroke with Affibody molecules targeting the inflam... 8M€ Cerrado

CPP2021-008378 Clinical trial to evaluate the administration of ApTOLL in a... 2K€ Cerrado

ApTOLL ApTOLL: An innovative neuroprotectant to reduce brain damage... 4M€ Cerrado

ARISE Affording Recovery In Stroke 16M€ Cerrado

SAVEBRAIN Proof of principle for a first in class neuroprotective ther... 150K€ Cerrado

SAF2008-00737 APLICACION DE FACTORES DE CRECIMIENTO ESTIMULANTES DEL DESAR... 145K€ Cerrado

Duración del proyecto: 6 meses Fecha Inicio: 2017-07-31
Fecha Fin: 2018-01-31

Líder del proyecto

ORPHIT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Each year, about 16 million strokes occur in the world causing millions of deaths and one third of patients experiencing permanent disability. The main treatment of stroke is thrombolytic agent recombinant tissue plasminogen activator (rtPA). Not all the patient can qualify for this treatment and it can be administered only in a limited time window. No existing drug is approved to protect against ongoing neuronal damage after the acute event. In this framework, our company, ORPHIT, a seed-stage biotech company, intends to be a pioneer by bringing clinical proof of concept of our peptide SYN1002 as suitable neuroprotective anti-inflammatory agent to treat stoke in acute phase that could be administered at multiple doses as complement to current thrombolytic treatments and also in patients who do not qualify for treatment with rtPA. This peptide is our lead product and has been initially developed as a potent anti-inflammatory substance in auto-immune pathologies with a clinical phase 1 study successfully documenting the safety and tolerability. Its properties make it a perfect match with current needs on Stroke treatment. Therefore, our solution is of interest for the pharmaceutical industry and health institutes who are currently in the search of a treatment that would be efficient and safe enough to be applicable to a larger part of the persons suffering from Stroke. The acute ischemic stroke (AIS) therapeutic market generated 400M€ in 2012 across the six major markets and is expected to reach 1.1 billion € by the end of 2017. SYN1002 sales at peak (2026) are expected to achieve 50% of market share, and a licensing deal at end of phase IIa would come out with a net present value of 265M€ for our company. In order to achieve this goal ORPHIT will realize a feasibility study aiming at strengthening SYN1002 preclinical package in AIS indication, confirming drug positioning through in depth market study, and draw a European business plan.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores